$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000162828018014023 Filed on November 09, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q4
Revenue	$18.00K	$18.00K	$18.00K
YoY Change	0.0%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.750M	$2.990M	$3.260M
YoY Change	-15.64%	9.12%	-31.8%
% of Gross Profit
Research & Development	$5.260M	$6.879M	$10.47M
YoY Change	-49.76%	-45.82%	-30.11%
% of Gross Profit
Depreciation & Amortization	$590.0K	$550.0K	$580.0K
YoY Change	1.72%	-5.17%	-15.94%
% of Gross Profit
Operating Expenses	$8.000M	$9.872M	$13.72M
YoY Change	-41.71%	-36.03%	-30.55%
Operating Profit		-$9.854M
YoY Change		-36.08%
Interest Expense	-$520.0K	$620.0K	-$800.0K
YoY Change	-35.0%	6.9%	196.3%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$8.500M	-$10.27M	-$14.51M
YoY Change	-41.42%	-35.12%	-27.52%
Income Tax	$60.00K	$0.00	-$36.31M
% Of Pretax Income
Net Earnings	-$8.563M	-$10.27M	-$14.45M
YoY Change	-40.73%	-35.1%	-27.83%
Net Earnings / Revenue	-47572.22%	-57072.22%	-80266.67%
Basic Earnings Per Share
Diluted Earnings Per Share	-$971.6K	-$1.180M	-$1.663M
COMMON SHARES
Basic Shares Outstanding	8.750M shares	104.8M shares	104.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.90M	$20.50M	$60.10M
YoY Change	-76.87%	-71.29%	-21.02%
Cash & Equivalents	$13.94M	$14.08M	$13.52M
Short-Term Investments	$0.00	$6.400M	$46.60M
Other Short-Term Assets	$1.140M	$717.0K	$1.506M
YoY Change	-24.3%	-59.08%	-63.75%
Inventory
Prepaid Expenses	$4.194M	$4.194M	$4.783M
Receivables	$0.00	$0.00	$400.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$19.30M	$25.44M	$66.74M
YoY Change	-71.09%	-68.03%	-23.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.806M	$8.324M	$9.708M
YoY Change	-19.59%	-18.17%	-17.94%
Goodwill
YoY Change
Intangibles	$500.0K	$676.0K	$775.0K
YoY Change	-35.48%	-15.71%	-23.65%
Long-Term Investments
YoY Change
Other Assets	$326.0K	$327.0K	$590.0K
YoY Change	-44.75%	6.51%	72.51%
Total Long-Term Assets	$8.632M	$9.327M	$11.07M
YoY Change	-22.04%	-17.32%	-16.03%
TOTAL ASSETS
Total Short-Term Assets	$19.30M	$25.44M	$66.74M
Total Long-Term Assets	$8.632M	$9.327M	$11.07M
Total Assets	$27.93M	$34.77M	$77.81M
YoY Change	-64.11%	-61.73%	-22.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.714M	$1.235M	$5.743M
YoY Change	-70.15%	-76.38%	-1.66%
Accrued Expenses	$1.625M	$1.856M	$4.941M
YoY Change	-67.11%	-61.09%	-11.4%
Deferred Revenue	$2.572M	$72.00K	$72.00K
YoY Change	3472.22%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$16.60M	$19.10M	$19.90M
YoY Change	-16.58%
Total Short-Term Liabilities	$26.65M	$25.65M	$32.60M
YoY Change	-18.26%	118.18%	136.11%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$309.0K	$373.0K	$0.00
YoY Change		6.27%	-100.0%
Total Long-Term Liabilities	$309.0K	$373.0K	$0.00
YoY Change		6.27%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.65M	$25.65M	$32.60M
Total Long-Term Liabilities	$309.0K	$373.0K	$0.00
Total Liabilities	$33.78M	$33.19M	$42.59M
YoY Change	-20.69%	-21.47%	-4.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$392.7M	-$384.2M	-$345.9M
YoY Change	13.55%	15.92%	26.53%
Common Stock	$386.9M	$385.8M	$381.2M
YoY Change	1.49%	1.5%	15.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.854M	$1.578M	$35.22M
YoY Change
Total Liabilities & Shareholders Equity	$27.93M	$34.77M	$77.81M
YoY Change	-64.11%	-61.73%	-22.7%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q4
OPERATING ACTIVITIES
Net Income	-$8.563M	-$10.27M	-$14.45M
YoY Change	-40.73%	-35.1%	-27.83%
Depreciation, Depletion And Amortization	$590.0K	$550.0K	$580.0K
YoY Change	1.72%	-5.17%	-15.94%
Cash From Operating Activities	-$4.010M	-$11.45M	-$11.10M
YoY Change	-63.87%	-1.8%	-26.49%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$20.00K	-$80.00K
YoY Change	-100.0%	-80.0%	-50.0%
Acquisitions
YoY Change
Other Investing Activities	$6.440M	$12.95M	$4.480M
YoY Change	43.75%	-154.64%	-71.19%
Cash From Investing Activities	$6.440M	$12.93M	$4.400M
YoY Change	46.36%	-154.33%	-71.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.570M	-890.0K	0.000
YoY Change		-102.06%	-100.0%
NET CHANGE
Cash From Operating Activities	-4.010M	-11.45M	-11.10M
Cash From Investing Activities	6.440M	12.93M	4.400M
Cash From Financing Activities	-2.570M	-890.0K	0.000
Net Change In Cash	-140.0K	590.0K	-6.700M
YoY Change	-97.91%	-92.33%	-2891.67%
FREE CASH FLOW
Cash From Operating Activities	-$4.010M	-$11.45M	-$11.10M
Capital Expenditures	$0.00	-$20.00K	-$80.00K
Free Cash Flow	-$4.010M	-$11.43M	-$11.02M
YoY Change	-63.61%	-1.12%	-26.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001505512
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8750343	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q3	dei	Entity Number Of Employees EntityNumberOfEmployees	25	employee
CY2017Q2	dei	Entity Number Of Employees EntityNumberOfEmployees	65	employee
	dei	Entity Registrant Name EntityRegistrantName	REGULUS THERAPEUTICS INC.
	dei	Trading Symbol TradingSymbol	RGLS
CY2018Q3	rgls	Cashand Cash Equivalentsand Marketable Securities CashandCashEquivalentsandMarketableSecurities	20500000	USD
	rgls	Proceeds From Capital Lease Financing ProceedsFromCapitalLeaseFinancing	0	USD
	rgls	Proceeds From Capital Lease Financing ProceedsFromCapitalLeaseFinancing	354000	USD
CY2017Q2	rgls	Reductionof Workforce ReductionofWorkforce	0.30
CY2018Q3	rgls	Reductionof Workforce ReductionofWorkforce	0.60
CY2017Q4	rgls	Rent Less Current Portion Liability RentLessCurrentPortionLiability	8072000	USD
CY2018Q3	rgls	Rent Less Current Portion Liability RentLessCurrentPortionLiability	7139000	USD
CY2017Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	373000	USD
CY2018Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	13000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5743000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1235000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-271000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-92000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2995000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1856000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-134000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-63000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	381199000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	385793000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1284000	USD
	us-gaap	Interest Paid InterestPaid	1573000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6531000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1390000	USD
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	106597	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	210816	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	575256	shares
CY2017Q4	us-gaap	Assets Assets	77809000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4374000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20222000	USD
CY2018Q3	us-gaap	Assets Assets	34768000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	66736000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	25441000	USD
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	57402000	USD
CY2018Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	20064000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	77000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	46632000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	6439000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	46555000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	6433000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14941000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13519000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14084000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5281000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	565000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1419000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8662435	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8750343	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8662435	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8750343	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	9000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	9000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15844000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-57438000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10257000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40076000	USD
CY2018Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	77000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	72000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1921000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	24000	USD
CY2017Q4	us-gaap	Debt Current DebtCurrent	19859000	USD
CY2018Q3	us-gaap	Debt Current DebtCurrent	19069000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1942000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1672000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-579000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-10.52
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.62
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1985000	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1292000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2736000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13752000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2993000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10115000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15835000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57596000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10273000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40146000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-139000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1124000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-360000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4509000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-652000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1138000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-54000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-54000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-418000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-1035000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-631000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-693000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2405000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1050000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	360000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-589000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	775000	USD
CY2018Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	676000	USD
CY2017Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	160000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	559000	USD
CY2018Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	201000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	483000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	580000	USD
	us-gaap	Interest Expense InterestExpense	1730000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	620000	USD
	us-gaap	Interest Expense InterestExpense	1848000	USD
	us-gaap	Interest Paid InterestPaid	1444000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	42593000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	33190000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	77809000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34768000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32600000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	25654000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	43415000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-258000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9538000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	40079000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47672000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39256000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-15828000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-57457000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-10273000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40146000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	306000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	15433000	USD
	us-gaap	Operating Expenses OperatingExpenses	56479000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	9872000	USD
	us-gaap	Operating Expenses OperatingExpenses	38835000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15415000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-56425000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9854000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38781000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1506000	USD
CY2018Q3	us-gaap	Other Assets Current OtherAssetsCurrent	717000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	590000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	327000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-16000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	19000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	70000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2018000	USD
CY2018Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2130000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	373000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	206000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	182000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	16000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	217000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	48539000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	54000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4783000	USD
CY2018Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4194000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	43411000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	219000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	58310000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	40101000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9708000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8324000	USD
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	833000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12697000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42727000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6879000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28720000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-345858000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-384161000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-344014000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	54000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6531000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4374000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1134000	shares
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	46555000	USD
CY2018Q3	us-gaap	Short Term Investments ShortTermInvestments	6433000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	35216000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	1578000	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7506529	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5463096	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8703626	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8688831	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-18-014023-index-headers.html	Edgar Link	pending
0001628280-18-014023-index.html	Edgar Link	pending
0001628280-18-014023.txt	Edgar Link	pending
0001628280-18-014023-xbrl.zip	Edgar Link	pending
ex-101x20180930.htm	Edgar Link	pending
ex-311x20180930.htm	Edgar Link	pending
ex-312x20180930.htm	Edgar Link	pending
ex-321x20180930.htm	Edgar Link	pending
ex-42x20180930.htm	Edgar Link	pending
ex42image1.jpg	Edgar Link	pending
ex42image2.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20180930.xml	Edgar Link	completed
rgls-20180930.xsd	Edgar Link	pending
rgls-20180930_cal.xml	Edgar Link	unprocessable
rgls-20180930_def.xml	Edgar Link	unprocessable
rgls-20180930_lab.xml	Edgar Link	unprocessable
rgls-20180930_pre.xml	Edgar Link	unprocessable
rgls20180930-10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2018 Q4 Form 10-Q Financial Statement

#000162828018014023 Filed on November 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2018 Q4 Form 10-Q Financial Statement

#000162828018014023 Filed on November 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls